share_log

On-body Drug Delivery Devices Market to Reach US$ 796.1 Million Valuation by 2034, Growing at 6.8% CAGR: TMR Report

On-body Drug Delivery Devices Market to Reach US$ 796.1 Million Valuation by 2034, Growing at 6.8% CAGR: TMR Report

據TMR報告,攜帶式藥物輸送設備市場將在2034年達到7970萬美元估值,以6.8%的複合年增長率增長。
PR Newswire ·  08/02 05:59

Companies in the on-body drug delivery devices market are working toward launching more efficient on-body delivery systems for injectables. They are also exploring the launch of multifunctional system in order to send drugs where they could be effective in the body's organs and tissues

在身體藥物遞送設備市場,公司正在努力推出更有效率的注射用在身體遞送系統。他們還在探討推出多功能系統,以便將藥物送到對身體器官和組織有效的位置。

WILMINGTON, Del., Aug. 2, 2024 /PRNewswire/ -- The on-body drug delivery devices market is poised to expand at a CAGR of 6.8% from 2024 to 2034. By the end of the aforementioned forecast period, the market is poised to total US$ 796.1 million in value terms. A basic advantage of an on-body drug delivery device is that it is able to accurately target specific cells and tissues. This minimizes the side-effects of drugs and increase therapeutic efficacy.

特拉華州威爾明頓,2024年8月2日/ PRNewswire /-在身體藥物遞送設備市場預計從2024年到2034年以6.8%的年複合增長率擴張。在上述預測期末,該市場總價值有望達到7,961,000美元。在身體藥物遞送設備最基本的優點是它能夠準確地將藥物定位到特定細胞和組織中,從而最小化藥物的副作用並增加治療效果。

An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical applications comprise proteins such as monoclonal antibodies (mAbs).

在身體藥物遞送裝置是一種貼在身體上的裝置,可皮下遞送大分子(生物製品)並設計用於週期性需要一定量配製藥物的治療。典型應用包括諸如單克隆抗體(mAb)這樣的蛋白質。

The advantages offered by on-body drug delivery devices include higher level of precision at lower dosing increments, home-use with bolus and/or basal profile, automatic needle insertion and retraction, occlusion detection, resusable/disposable concept supporting sustainability, and use of standard glass cartridges. Research states that targeted drug delivery results in enhanced pharmacokinetics such as improved absorption, distribution, metabolism, and excretion (ADME).

在身體藥物遞送裝置提供的優勢包括更高精度的低劑量增量,具有豁免和/或基礎輪廓的家庭使用,自動針頭插入和回退,阻塞檢測,可支持可持續性的可重複使用和可丟棄的概念以及玻璃標準膠囊的使用。研究表明,靶向藥物遞送可以提高藥物動力學,例如改善吸收,分佈,代謝和排泄(ADME)。

Request a PDF Sample of this Report Now!

立即請求本報告的PDF樣本!

Increasing preference for advanced drug delivery systems has widened the scope for on-body drug delivery devices. Advanced drug delivery technologies have proven to enhance treatment outcomes in various ways, which include enhancement of therapeutic efficacy, increasing patient compliance, reducing toxicity, and facilitating novel medical treatments.

高級藥物遞送系統的偏好增加了在身體藥物遞送設備的範圍。先進的藥物遞送技術已經被證明可以以各種方式增強治療效果,包括增強治療療效,提高患者依從性,減少毒性和促進新的醫學治療。

Key Takeaways from the Market Study

市場研究的關鍵要點

  • The market for on-body drug delivery is poised to accumulate a value of US$ 416.8 million in 2024.
  • The on-body drug delivery devices market is poised for a 1.9x growth from 2024 to 2034.
  • By application, cancer is expected to emerge as an important area for on-body drug delivery devices use.
  • By product type, both wearable and auto-injectors are expected to enjoy heightened demand throughout the forecast period.
  • Hospitals are the main sites for availing on-body drug delivery devices for patients.
  • 在身體藥物遞送市場在2024年積累的價值達到4,1680萬美元。
  • 在身體藥物遞送設備市場在2024年至2034年預計增長1.9倍。
  • 按應用分類,癌症預計將成爲在身體藥物遞送設備使用的重要領域。
  • 按產品類型分類,可穿戴和自動注射器預計在整個預測期內需求增加。
  • 醫院是爲患者提供在身體藥物遞送設備的主要場所。

Key Market Drivers and Trends

關鍵市場驅動因素和趨勢

  • On-body drug delivery devices help in obtaining enhanced drug safety along with patient compliance. These devices are designed such that therapeutic levels of drug are maintained, and side-effects and overdose of drugs can be reduced. Besides, drugs can be delivered with short in-vivo half-lives.
  • Targeted drug delivery systems such as on-body drug delivery devices are capable of concentrating a medicine's active ingredient at site of a lesion/anatomical target. This keeps the drug at effective concentration on targeted organs for a longer duration, facilitating prescription of medicines at a lower dose.
  • 在身體藥物遞送設備有助於獲得增強的藥物安全性和患者依從性。這些設備的設計是爲了維持藥物的治療水平,並且可以減少藥物的副作用和過量用藥。此外,可以使用內在半衰期短的藥物進行輸送。
  • 靶向藥物遞送系統,例如在身體藥物遞送設備,能夠將一種藥物的活性成分濃縮到病竈/解剖靶點的位置。這可以使藥物在靶向器官上保持有效濃度更長時間,促進在較低劑量下的藥物處方。

On-body Drug Delivery Devices Market Report Scope:

在身體藥物遞送裝置市場報告範圍:

Report Coverage

Details

Forecast Period

2024-2034

Base Year

2020-2022

Size in 2023

US$ 390.7 Mn

Forecast (Value) in 2034

US$ 796.1 Mn

Growth Rate (CAGR)

6.8 %

No. of Pages

136 Pages

Segments covered

By Product Type, By Application, By End-user

報告涵蓋內容

詳情

預測期

2024-2034

基準年

2020-2022

2023年規模

3,907萬美元

2034年預測(價值)

7,961萬美元

增長率(年複合增長率)

6.8%

頁面數

136頁

所涵蓋的片段

按產品類型,按應用,按最終用戶

Unlock Growth Potential in Your Industry! Download PDF Brochure:

解鎖您行業的增長潛力!下載PDF手冊:

Regional Profile

區域概述

  • North America expects to witness substantial progress with respect to on-body drug delivery devices sales. This is attributed to growing demand for advanced drug delivery systems such as metered-dose inhalers and sensor-embedded devices. As per a study published by CIHI in April 2021, more than 3 million acute inpatient hospitalizations were witnessed in Canada from 2019 to 2020.
  • The market in Europe is expected to see substantial expansion. Europe's market growth is ascribed to rise in awareness about advanced drug delivery devices and rise in adoption of the advanced products.
  • Various clinical trials are being conducted regularly for novel products and introduction of new products by the key participants. Along these lines, in April 2021, Medtronic launched its extended infusion set in select European nations. It can be worn for close to a week.
  • 預計北美地區在體內藥物遞送裝置銷售方面取得重大進展。這歸因於對計量吸入器和傳感器嵌入式裝備等先進藥物遞送系統日益增長的需求。根據CIHI於2021年4月發佈的一項研究,加拿大在2019年至2020年期間共發生了超過30萬例急性住院治療。
  • 歐洲市場預計將迎來實質性的擴張。歐洲市場增長歸因於對先進藥物遞送裝置的認知提高和對先進產品的採用增加。
  • 關鍵參與者在爲新產品進行各種臨床試驗,並推出新產品。在此基礎上,美敦力於2021年4月在歐洲部分國家推出了其延長輸注套件。該套件可以佩戴近一週時間。

Competitive Landscape

競爭格局

Key participants in the on-body drug delivery devices market are launching new products to strengthen their position. For instance, in September 2023, Corium, Inc. introduced ADLARITY, a donepezil transdermal system in the U.S. to treat patients contracting mile-to-severe Alzheimer's.

體內藥物遞送裝置市場的關鍵參與者正在推出新產品以加強其地位。例如,2023年9月,Corium, Inc.在美國推出了ADLARITY,一種合成多巴胺轉移酶抑制劑透皮系統,用於治療輕度至重度阿爾茨海默病患者。

In August 2022, Baxter announced that it had obtained clearance from the U.S. FDA for usage of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software. These infusion pumps deliver small quantities of fluid at low rates in neonatal, pediatric, or anesthesia care settings with utmost precision.

在2022年8月,巴克斯特宣佈已獲得美國FDA批准使用帶有Dose IQ安全軟件的Novum IQ注射泵。這些注射泵以極高的精度在新生兒、兒科或麻醉護理環境中以低速輸送小量液體。

Enable Injections Inc., NOVO Engineering, Elcam Medical, Battelle, and Gerresheimer AG are some of the key players covered in the on-body drug delivery devices market report.

On-body藥物遞送設備市場報告涵蓋了Enable Injections Inc.、NOVO Engineering、Elcam Medical、Battelle和Gerresheimer AG等關鍵參與者。

Key Players Profiled

關鍵參與者簡介

  • Enable Injections Inc.
  • NOVO Engineering
  • Elcam Medical
  • Battelle
  • Gerresheimer AG
  • Enable Injections Inc.
  • NOVO Engineering
  • Elcam Medical
  • Battelle
  • Gerresheimer AG

Recent Market Developments

最近的市場發展

  • In January 2024, Medtronic received CE Mark approval for MiniMed 780G system, in collaboration with Simplera Sync. MiniMed 780G is one of the automated insulin delivery system, which is equipped with meal detection technology and makes provision for automatic adjustments as well as corrections to the levels of sugar every five minutes.
  • In February 2023, Innovation Zed received CE mark for its InsulCheck DOSE, one of the single unit add-on device for insulin pen injectors.
  • 在2024年1月,美敦力與Simplera Sync合作獲得了MiniMed 780G系統的CE Mark批准。MiniMed 780G是自動胰島素遞送系統之一,配備有餐後檢測技術,並提供每五分鐘對血糖水平的自動調整和修正功能。
  • 在2023年2月,Innovation Zed獲得其InsulCheck DOSE的CE標誌,該裝置是用於胰島素筆注射器的單元式附加設備之一。

Key Segments Profiled

關鍵細分市場簡介

Product Type

產品類型

  • Wearable Injectors
  • Auto-injectors
  • Patches
  • Others
  • 可穿戴注射器
  • 自動注射器
  • 貼片
  • 其他

Application

應用

  • Cardiovascular Diseases
  • Cancer
  • Autoimmune Diseases
  • Diabetes
  • Others (Orthopedic Disorders, etc.)
  • 心血管疾病
  • 癌症
  • 自身免疫性疾病
  • 糖尿病
  • 其他(矯形障礙等)

End User

最終用戶

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • Others (Research Institutes, etc.)
  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他(研究院等)

Region

地域板塊

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
  • 北美洲
  • 歐洲
  • 亞洲太平洋
  • 拉丁美洲
  • 中東和非洲

Purchase the Report for Market-Driven Insights:

購買報告以獲取市場驅動的見解:

More Trending Report by Transparency Market Research:

更多熱門報告請參見透明市場研究:

  • Mechanical Thrombectomy Devices Market - In 2022, the Mechanical Thrombectomy Devices market was valued at USD 1.1 billion. It is projected to grow at a CAGR of 6.4% from 2023 to 2031, reaching over USD 1.8 billion by the end of 2031.
  • Sanitization Robots Market - The Sanitization Robots market was valued at USD 927.3 million in 2022 and is anticipated to grow at a remarkable CAGR of 19.2% from 2023 to 2031. By 2031, the market is expected to surpass USD 4.8 billion.
  • Microcatheter Market - Valued at USD 799.7 million in 2022, the Microcatheter market is estimated to grow at a CAGR of 5.3% from 2023 to 2031. This growth is projected to elevate the market value to USD 1.3 billion by the end of 2031.
  • Infant Resuscitators Market - The global Infant Resuscitators market, valued at USD 253.1 million in 2022, is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2031. This growth is projected to increase the market value to over USD 401.4 million by the end of 2031.
  • 2022年,機械性血栓切除裝置市場價值達到11億美元。預計2023年至2031年將以6.4%的複合年增長率增長,到2031年底將達到18億美元以上。
  • 消毒機器人市場價值在2022年爲9,273萬美元,並預計從2023年到2031年以驚人的19.2%的複合年增長率增長。到2031年,市場預計將超過48億美元。
  • 2022年微導管市場價值爲7,997萬美元,預計在2023年至2031年以5.3%的複合年增長率增長。預計到2031年底,市場價值將增加至13億美元。
  • 全球嬰兒復甦器市場價值在2022年爲2,531萬美元,預計從2023年到2031年將以5.2%的複合年增長率增長。這種增長預計將使市場價值到2031年底超過4,014萬美元。

About Transparency Market Research

關於透明市場研究

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

總部位於美國特拉華州威爾明頓的全球市場研究公司Transparency Market Research提供定製研究和諮詢服務。我們獨特的定量預測和趨勢分析相結合,爲數千位決策者提供前瞻性的見解。我們經驗豐富的分析師、研究人員和顧問使用專有的數據來源和各種工具和技術來收集和分析信息。

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

我們的數據倉庫由一組研究專家不斷更新和修訂,以反映最新的趨勢和信息。透明市場研究具備廣泛的研究和分析能力,採用嚴格的一手和二手研究技術,爲商業報告開發獨特的數據集和研究材料。

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website:
Email: [email protected]
Follow Us: LinkedIn| Twitter| Blog | YouTube

聯繫方式:
透明度市場研究有限公司
總部位於市中心,
N. West Street,1000號,
套房 1200,特拉華州威明頓19801 美國
電話:+1-518-618-1030
美國-加拿大免費電話:866-552-3453
網站:
電子郵件:[email protected]
關注我們:LinkedIn | Twitter | 博客 | YouTube

Logo:

徽標:

SOURCE Transparency Market Research

消息來源:透明度市場研究

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論